News | October 04, 2013

Piramal Imaging Responds to CMS-Proposed Coverage Decision for Beta-Amyloid PET

October 4, 2013 — Piramal Imaging announced the company has submitted a detailed response to the Council on Medical Service (CMS) regarding the draft decision to limit Medicare coverage of beta-amyloid positron emission tomography (PET) imaging in dementia and neurodegenerative disease.[1] Piramal Imaging's response, originally submitted on July 29, 2013, was posted on CMS's website as part of the public comment process, which was open through August 2. As of August 8, CMS's website indicated more than 200 people had posted responses. Piramal Imaging strongly encourages the public to continue to submit evidence to CMS showing why beta-amyloid imaging is a medically necessary diagnostic tool for appropriate Medicare populations by sending information to [email protected].

In Piramal Imaging's letter to CMS, the company expressed concerns that the CMS draft coverage decision is overly restrictive and, if finalized in its current form, would place an undue burden on physicians, patients and caregivers by delaying the definitive diagnosis of certain types of dementia and neurodegenerative diseases, including Alzheimer's disease (AD).

The letter addresses four specific areas of concern and offers recommendations for consideration which are highlighted below:

  1. Agreement with CMS's determination that there is a clear benefit to rule out AD in precisely defined patient populations where a differential diagnosis is clinically difficult and to distinguish from other forms of dementia such as frontotemporal dementia. Piramal Imaging has requested Medicare coverage for these patients without requiring enrollment in a clinical trial. Clinical presentation of early onset AD can be difficult to distinguish from other forms of dementia and can present with many atypical features, which obfuscate the diagnosis. The results of beta-amyloid PET imaging thus can help the physician with the differential diagnosis of the patient, leading to identification of other appropriate treatments and tests to administer.[2] It can help the physician determine whether further testing is needed and to select pharmacologic and non-pharmacologic options for the patient's treatable conditions, and it may enable the patient to forgo potentially futile testing and treatment. Furthermore, Piramal Imaging believes there is a patient population for which beta-amyloid PET imaging meets the "reasonable and necessary" threshold for the diagnosis of disease: patients meeting the Appropriate Use Criteria (AUC) developed by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimer's Association.
  2. CMS should establish a clear standard of the level of evidence required to expand coverage. CMS should approve any clinical trials that are likely to expeditiously answer one or several of the three proposed research questions without onerous restrictions. Furthermore, CMS should ensure that it approves a sufficient range of clinical trials, allowing for a variety of practical clinical trial designs, providing they address relevant endpoints and help answer all or at least one of CMS' research questions.
  3. CMS should state in its final decision memo that once a clinical trial meets endpoints as agreed upon by CMS, it will expand Medicare coverage in a corresponding manner without any undue delay. The decision to expand coverage based on the results of a successful clinical trial should not unnecessarily delay the National Coverage Determination process. Medicare beneficiaries should not lose access to diagnostic technologies that have demonstrated clinical benefits in patient outcomes.
  4. CMS should not require a postmortem autopsy as an endpoint for any CMS-approved clinical trial. Several pivotal autopsy studies demonstrate amyloid imaging agents bind to beta-amyloid in the brain; therefore, further biomarker studies are redundant. According to the Agency for Healthcare Research and Quality (AHRQ) Clinical Research Standard no. 3, "the research study does not unjustifiably duplicate existing studies." Therefore, additional post-mortem autopsy studies would not fulfill the above AHRQ standard. In addition, Medicare beneficiaries may understandably be very uncomfortable or unwilling to agree to such a requirement to undergo a diagnostic imaging scan.


For more information:



[1]Centers for Medicare & Medicaid Services. Proposed decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). Published July 3, 2013. Accessed August 8, 2013

[2]Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association [published online ahead of print January 28, 2013]. Alzheimer's Dement. doi:10.1016/j.jalz.2013.01.002

Related Content

FDA Clears CereMetrix’s Neuroimaging Analytics and Clinical Workflow Platform
Technology | Neuro Imaging | March 15, 2018
March 15, 2018 – CereMetrix, a subsidiary of CereHealth Corp., ha
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
MedyMatch Receives FDA Device Designation for Intracranial Hemorrhage Software
News | Computed Tomography (CT) | February 01, 2018
February 1, 2018 – MedyMatch Technology, a company focused on helping physicians provide accurate patient assessment
Machine Learning Techniques Generate Clinical Labels of Medical Scans
News | Artificial Intelligence | January 31, 2018
Researchers used machine learning techniques, including natural language processing algorithms, to identify clinical...
Brain-scan guided emergency stroke treatment can save more lives
News | Neuro Imaging | January 25, 2018
January 25, 2018 – Advances in brain imagin...
PET Tracer Measures Damage From Multiple Sclerosis in Mouse Models
News | PET Imaging | January 24, 2018
January 24, 2018 — The loss or damage of myelin, a cellular sheath that surrounds and insulates nerves, is the hallma
Overlay Init